HomeProductsBioactive CompoundsMetabolic EnzymesACATPactimibe
Chemical structure of CAS 189198-30-9

Pactimibe

In Stock•Starting at $603 for 1 mg•Purity ≥ 98.07%
CAS No.189198-30-9
MDL No.N/A
MFC25H40N2O3
MW416.60
InChI KeyTXIIZHHIOHVWJD-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98.07%$603In Stock
5 mg98.07%$1316In Stock
10 mg98.07%$2331In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.189198-30-9
Product NamePactimibe
Heavy Atom Count30Rotatable Bond Count10
Atom Stereo Count0Bond Stereo Count0
HBA3HBD2
TPSA69.640 ŲCharge0
Exact Mass416.30389Complexity777.82
pKa3.605XLogP5.638

Related Articles

Studies related to this compound and its mechanism of action

ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.

Atherosclerosis • Vol. 190, Issue 2 • 2007
PMID: 16626720DOI: 10.1016/j.atherosclerosis.2006.03.007

Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor.

European journal of pharmacology • Vol. 543, Issue 1-3 • 2006
PMID: 16814766DOI: 10.1016/j.ejphar.2006.05.036

Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.

European journal of pharmacology • Vol. 540, Issue 1-3 • 2006
PMID: 16730694DOI: 10.1016/j.ejphar.2006.04.022

Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits.

European journal of pharmacology • Vol. 539, Issue 1-2 • 2006
PMID: 16690054DOI: 10.1016/j.ejphar.2006.03.078

Documentation

Similar Products